What is Endogenex?
Endogenex is at the forefront of developing a groundbreaking treatment for type 2 diabetes by targeting the duodenum, a factor increasingly recognized as a potential root cause of the condition. The company's proprietary outpatient endoscopic procedure utilizes non-thermal pulsed electric fields (PEF) energy. This advanced technique is designed to treat inflamed and dysfunctional duodenal tissue associated with diabetic duodenopathy, thereby initiating the body's natural cell regeneration processes. Endogenex aims to restore duodenal health, moving beyond mere symptom management to potentially slow or halt disease progression, thereby redefining the landscape of diabetes care.
How much funding has Endogenex raised?
Endogenex has raised a total of $190.3M across 4 funding rounds:
Series A
$34M
Series B
$18.3M
Series C
$88M
Series C
$50M
Series A (2023): $34M with participation from Longitude Capital
Series B (2023): $18.3M, investors not publicly disclosed
Series C (2024): $88M supported by Lumira Capital and Hatteras Venture Partners
Series C (2026): $50M featuring Arboretum Ventures
Key Investors in Endogenex
Lumira Capital
Lumira Ventures is a leading Canadian life sciences venture capital firm that invests in healthcare innovators across various stages, focusing on improving patient outcomes through impactful products.
Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm dedicated to building transformative companies in biotech, MedTech, and HealthTech, providing capital and strategic support to advance human medicine.
Arboretum Ventures
Arboretum Ventures is a healthcare venture capital firm with extensive experience in investing in early-stage startups that aim to improve patient outcomes and reduce healthcare costs.
What's next for Endogenex?
The substantial enterprise-level funding, including the recent major strategic investment, positions Endogenex for accelerated growth and the scaling of its innovative endoscopic procedure. This capital infusion is expected to fuel further clinical development, regulatory approvals, and market penetration. The company's focus on a science-driven, gut-centric approach to diabetes care suggests a strategic expansion into broader gastrointestinal health applications. With a clear trajectory from seed-stage development through Series C, Endogenex is poised to make a significant impact on how type 2 diabetes is managed and treated globally.
See full Endogenex company page
